Zeta Myogenin Antibody. Zeta’s monoclonal mouse antibody recognizes Myogenin, a member of the MyoD family of myogenic basic helix-loop-helix (bHLH) transcription factors expressed early in skeletal muscle differentiation that also includes MyoD, Myf-5, and MRF4. Expression of Myogenin is restricted to cells of skeletal muscle origin. Myogenin is therefore a useful marker for tumors of the muscle lineage, being strongly expressed in alveolar rhabdomyosarcomas. Myogenin is a sensitive and specific for rhabdomyosarcoma.
MyoD family members are expressed exclusively in skeletal muscle and play a key role in activating myogenesis by binding to enhancer sequences of muscle-specific genes. The regulatory domain of MyoD is approximately 70 amino acids in length and includes both a basic DNA binding motif and a bHLH dimerization motif. MyoD family members share about 80% amino acid homology in their bHLH motifs.
The Myogenin antibody labels the nuclei of myoblasts in developing muscle tissue and is expressed in tumor cell nuclei of rhabdomyosarcoma and some leiomyosarcomas. Myogenin provides focal nuclear staining in desmoid tumors, infantile myofibromatosis, synovial sarcoma, infantile fibrosarcoma, entrapped atrophic or regenerative skeletal muscle. The Myogenin antibody has positive nuclear staining may occur in Wilms’ tumor.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.